$150.20
−0.28%Jun 23, 2026, 19:51 UTC
Novartis AG reported early data from an actinium-based radiopharma drug showing anti-tumor activity in advanced prostate cancer.
Source:Jun 18, 2026, 11:58 UTC
Curium prevailed in a patent dispute brought by Novartis subsidiary Advanced Accelerator Applications in the Delaware U.S. District Court, with all relevant patent claims ruled invalid and not infringed.
Source:
← PreviousPage 3